reveals that in some cases the conclusions were based on very few inagglutinable cell counts. Loutit (2) affirmed this paucity of data in a published discussion of his own studies.
Acceptance of the conclusions that adult normal erythrocytes survived normally in the circulation of the untreated patient with pernicious anemia, together with the curative effect of B12 on the disease and the demonstrated influence of B12 on the cells of the bone marrow, seem to have led to the concept that hemolysis plays but a minor role in the oligocythemia of the disorder.
The purposes of the present studies were (a) to ascertain whether patients with untreated pernicious anemia possess a hemolytic mechanism which acts upon normal adult erythrocytes, (b) to assess the effect of vitamin B12 upon such a mechanism, if present, and (c) to measure the rate of release of the patient's erythrocytes to the circulation in untreated pernicious anemia. The experiments consisted of transfusing normal fresh adult erythrocytes of group 0 to patients with pernicious anemia in relapse, or in various stages of treatment with B12, who belonged to blood groups A or B. The transfused cells were measured by the method of differential agglutination. In one case the erythrocytes from a patient with untreated pernicious anemia were transfused to a normal subject and similar measurements were made. With suitable assumptions, the rate of loss of transfused cells from the circulation was calculated. With these data as points of reference, the erythrocyte counts of the subject were employed to estimate the rate of release of the subject's own cells to the circulation, termed briefly rate of erythrocyte release. This rate is not necessarily equal to the rate of nu -191 H. E. HAMILTON, E. L. DEGOWIN, k. P. SHEETS, C. fl. JANNEY, ANI J. A. ELLIS merical production of erythrocytes in the bone marrow. The present study does not deal with the rate of formation of hemoglobin nor any other erythrocyte components.
METHODS
Patients. All had proven Addisonian pernicious anemia. In each instance the diagnosis was made by the history, the physical findings, the demonstration of a hyperchromic anemia, the characteristic cytologic picture in the bone marrow of pernicious anemia in relapse, and achlorhydria after stimulation with histamine intramuscularly. In all cases the injection of B12 intramuscularly resulted in prompt reticulocytosis and subsequent rise of erythrocyte counts to the normal range. These phenomena were accompanied by characteristic improvement in the clinical picture. Other features of pernicious anemia were usually present, such as leukopenia, thrombocytopenia, atrophic gastritis, elevated serum bilirubin level, and increased excretion of urobilinogen in the urine. Observations of the patients for many months confirmed the absence of neoplasms, sprue, gastrocolic fistulae, diseases of the liver, intestinal parasites, chronic hemorrhage, generalized infections, azotemia, and myxedema. The pertinent data are found in Table I. Donors. Blood was collected from healthy young men of group 0 and transfused to patients of group A or B with compatible subtypes of Rh. Previously blood from the donors had been transfused to other recipients and normal survival had been demonstrated.
Transfusions. Approximately 500 ml. of blood was employed for each transfusion. The donor's blood was collected in 3.2 per cent sodium citrate solution (Na,C.H,01 2 H2O) and stored at about 40 C. for less than 18 hours. The supernatant plasma was decanted and the cells washed once with 0.9 per cent NaCl solution. Counts of the donor's erythrocytes were made and a measured volume of blood was prepared and injected by gravity, as described previously. During the first 24 hours after transfusion frequent samples of the recipient's plasma were examined and found to contain no abnormal amounts of bilirubin or hemochromogens.
Erythrocyte counts. After transfusion the donor's cell counts were estimated in the recipient's circulation by a modification of the Ashby differential agglutination technique previously described and evaluated by us (7, 8 
Results
The observed values for the erythrocyte counts in these studies are presented in Table II In charts IA and 1B, when injections of B.2 were started 12 and 9 days before transfusion, there was no loss of cells by random destruction. In chart 1C, when B, was started 3 days before transfusion, there was random loss of the donor's erythrocytes for the first 15 days; thereafter the remaining cells survived normally. Mathematical considerations and facts established in the following studies warrant the interpretation that only a few transfused cells were damaged and destroyed at random.
Cells transfused one day before B. therapy was begun are shown in chart 1D to have been lost at random with the constant rate of 0.43 per cent. 1).
FIG. 2. RANDOM LOSS OF FRESH NORMAL ERYTHROCYTES TRANSFUSED TO PATIENTS WITH PERNICIOUS ANEMIA TREATED WITH B,, AT VARIOUS TIMES
The methods of plotting and interpretation are the same as in Figure 1 . Cells transfused 4 days before therapy with B. are shown in chart 2A to have been lost randomly at a constant rate of 1.2 per cent. In chart 2B the erythrocytes in the first transfusion were also injected 4 days before therapy with B. was begun and were lost at random with the rate accelerating as the cells became older. During the first 40 days of the study the rate of random loss was approximately 0.9 per cent and from 60 to 90 days the rate was about 3.3 per cent. The second transfusion of cells from the same donor was given 97 days after the first and the donor's cells exhibited a constant random loss of about 0.4 per cent, showing that the destructive mechanism in this patient had not been completely abolished by B1 treatment for at least 97 days.
Cells transfused 5 days before B. therapy was begun are shown in chart 2C to have been lost randomly at a constant rate of 0.2 per cent. In chart 2D, the erythrocytes were transfused 65 days before therapy with B1, was begun. During the first 60 days of the study the cells were lost at random at a constant rate of 1.4 per cent. Thereafter there was sharp acceleration in the rate of random loss, forming a curve comparable to that obtained from the first transfusion in 2B.The similarity in the shape of the two curves excludes the probability that the acceleration noted in 2D had any but a coincidental relation to the beginning of B. therapy. _ from random destruction and supporting the assumption that the majority of the cells of the transfused population had a potential life span of approximately 120 days.
Case 2 ( Figure 1B) mal erythrocytes of group 0 Rh. positive. The N.Q values for the resulting inagglutinable cell counts fit a straight line with a slope which indicates a random loss of 0.43 per cent of the remaining cells each day, in addition to the loss by aging. The conclusion was drawn that a hemolytic mechanism was present which injured the adult normal erythrocytes soon after transfusion so that they were subsequently lost at random, despite concomitant therapy with B,,. His blood was found to belong to group A Rh. positive and, four days before therapy with B,, was begun, he was transfused with fresh normal erythrocytes of group O Rh. positive. The NoQ values for the resulting inagglutinable cell counts fit a straight line with a slope indicating random destruction of the transfused erythrocytes at a rate of 1.2 per cent per day. Eight months after the study he was readmitted to the hospital in cardiac failure but there had been no relapse of the pernicious anemia under treatment continued at home.
Case 6 ( Figure 2B ), E. Nie., a 66-year-old woman was admitted January 7, 1950. Pallor had been noticed for six years and progressive weakness had finally confined her to bed. No therapy had been given for the anemia. Soon after admission she was transfused with 1,000 ml. of blood of group A Rh. positive, the group to which she belonged. At the beginning of this study she was transfused with fresh normal erythrocytes of group 0 Rh, positive. Four days later daily injections of 15 micrograms of B., were begun and continued for 30 days; thereafter similar doses were given at weekly intervals. Gradual symptomatic improvement was noted and the abnormal neurologic signs disappeared in several months. Two years later the patient was in good health with con- tinued antianemic therapy and her hematologic findings were normal. Ninety-seven days after the first transfusion of heterologous group a second transfusion of erythrocytes from the same donor was given. During the first 24 days of the second study weekly injections of 15 micrograms of B12 were given and thereafter injections were given every two weeks.
The N.Q values from the first tagged transfusion fit a curve which indicates random destruction at an accelerating rate. Those from the second transfusion consist of only 13 counts which are probably insufficient to determine a curve with any accuracy. However, the values available fit a straight line with much less slope than that characterizing the first transfusion. This is certainly evidence that the first curve could not have been the result of isosensitization to antigens in the transfused erythrocytes.
Case 7 ( Figure 2C) Figure 2B .
Case 9 (Figure 3) , A. Joy., a 50-year-old woman, was admitted April 7, 1951 with weakness which confined her to bed. She had previously been known to have schizophrenia but had received no therapy for anemia. She 
Summary
Normal adult erythrocytes survived normally when transfused to two patients with pernicious anemia who had been given injections of B12 for 9 and 12 days, respectively, before the transfused cells were exposed to the milieu of the patient ( Figures 1A and 1B) . In five other patients ( Figures 1D, 2A , 2B, 2C, and 2D) normal adult erythrocytes were lost by random destruction when B12 therapy was begun respectively 1, 4, 4, 5, and 65 days after transfusion. In another patient ( Figure 3 ) B12 therapy was begun 9 days before transfusion and the transfused normal erythrocytes survived normally for approximately 20 days after cessation of therapy. Thereafter, however, the transfused erythrocytes were lost by random destruction. In none of the studies alluded to was the random loss of erythrocytes abated by subsequent administration of B12. Finally, a transition stage in this series of assays of B12 therapy seems to have been observed ( Figure 1C ) in a patient who was treated with B12 for 3 days before normal adult erythrocytes were transfused. The transfused cells were lost at random for the first 15 days or so, thereafter normal survival of the remainder occurred. This could be interpreted as damage to only a few transfused cells, irrespective of their age.
It should be emphasized that the observed rates of loss from random destruction were slow, ranging from 0.2 per cent to 1.4 per cent of the remaining erythrocytes per day. This is a much slower rate than has been observed in the case of proven hemolysis from isosensitization in transfusion. Furthermore, in Cases 6 and 9 subsequent studies were made after adequate treatment of the patients with B12. Erythrocytes from the same donors were retransfused and found to survive normally in Case 9 and to be lost randomly at a much slower rate than before in Case 6.
LOSS IN NORMAL SUBJECT OF ERYTHROCYTES FROM PERNICIOUS ANEMIA COMPARED TO LOSS OF NORMAL CELLS IN THE PATIENT
Case 10 (Figure 4) 
Method of analysis
In a previous paper (10) graphic analyses were derived and described in detail by which the expected erythrocyte counts can be computed from the demonstrated rate of loss of transfused cells. The expected erythrocyte counts can then be compared with the observed values and certain conclusions can be made regarding the rate of release of the patient's own erythrocytes to the circulation. For this purpose only two measurements are required: the inagglutinable cell counts and the total erythrocyte counts over a long period of time, so that smoothed curves can be constructed with some validity.
When the conditions of the experiment indicate that the subject is in the steady state of random destruction of erythrocytes, the resulting expected level of erythrocyte counts can be computed on the assumptions: (a) The rate of cell release to the circulation continues to be normal; (b) the rate of random destruction of transfused erythrocytes is the same as that of the subject's cells; (c) the 199 H. E. HAMILTON, E. L. DEGOWIN, R. F. SHEETS, C. D. JANNEY, AND J The solid circles in the upper section are the observed values for the patient's erythrocyte counts, obtained by subtracting the inagglutinable cell count from the total cell count taken simultaneously. The solid horizontal line indicates the observed erythrocyte level of the patient during the steady state of random destruction, before B1, therapy. The broken horizontal line represents the expected erythrocyte level, estimated for the steady state of random destruction, assuming a normal rate of erythropoiesis, and assuming the rate of random destruction to be the same as that of the transfused cells. It was previously shown that once the transfused cells are damaged in the milieu of the patient with B., deficiency, their rate of random loss is unaltered by subsequent treatment. The open circles, connected by broken lines, are the expected cell counts of the patient during the recovery phase of random destruction, assuming a normal rate of cell release beginning shortly after inception of B., therapy, and assuming that the pre-existing crops of the patient's erythrocytes continue to be lost at random as in the steady state of random destruction.
In chart 5A the expected level of the patient's erythrocytes during the untreated state was estimated at 3.77 millions per mm.', as compared with the observed level of 1.00 million. The discrepancy can be explained as the result of maturation arrest. B., therapy was started 5 days after transfusion. The patient's erythrocyte counts increased faster than was expected and the rate of cell release attained a maximum of twice the normal 25 days after the inception of treatment Therapy with B,. was initiated 9 days before transfusion in the study in 5B. But treatment was discontinued 15 days after transfusion, and resumed on the 62nd day after transfusion. The expected level of the patient's erythrocytes before treatment was estimated to be 2. Figure 6 (10) . Rr.c = Ro( w') where R. is the normal eythrocyte level, W is the stippled area in Figure 10 (10), and W+W'=the area of the enclosing rectangle.
The expected values R' and R,.r were then compared with the observed values for the recipient's cell counts (total erythrocyte count minus contemporaneous inagglutinable cell count) and significant discrepancies were interpreted as acceleration or deceleration in the normal rate of erythrocyte release to the circulation.
Results
Data from 6 of the 10 cases (Table II) were available for this part of the study because random destruction of normal transfused erythrocytes had been demonstrated and the rate of random loss estimated. The evidence obtained from the cross transfusion experiment in Case 10 supported the assumption that the erythrocytes of the patient with pernicious anemia were destroyed at random at least as fast as the normal adult erythrocytes transfused to the patient with untreated, or inadequately treated, pernicious anemia. Since the disappearance curves of normal erythrocytes, transfused before adequate B12 therapy had been given, were not altered by subsequent administration of the vitamin, it was thought to be a safe assumption that the rate of loss from curves obtained during therapy were at least not less than the rate before therapy was begun. Any calculations resulting from the use of these disappearance curves would, therefore, be on the conservative side when the contribution of hemolysis to the erythrocyte level was estimated.
Erythrocyte levels attributable partially to maturation arrest. The data from two patients can be interpreted as demonstrating the effect of maturation arrest on the erythrocyte levels. In Case 7 ( Figure 5A ) the observed erythrocyte level in the steady state of random destruction of erythrocytes was approximately 1.00 million per mm.8 Assuming that the patient's cells were destroyed at the same rate as the transfused erythrocytes, and assuming the rate of random destruction determined by transfusion obtained also before transfusion, the expected level of the patient's cell counts was 3.77 millions per mm.8 The discrepancy between observed and expected levels could be attributed to maturation arrest, but the difference between the expected and the normal level is ascribed to the hemolytic mechanism. Therapy with B12 caused a rapid increase in the erythrocyte counts of the patient, which in 25 days of treatment doubly exceeded the number expected if the hemolytic mechanism had merely been inhibited and the rate of erythrocyte release to the circulation had continued normal. This finding is ascribed to an actual acceleration of the rate of cell release to twice the normal rate.
The data in Case 9 (
Figure 5B Figure 5 . The bone marrow of all patients exhibited the cytologic findings of maturation arrest. The coincidence of observed erythrocyte levels and those expected on the assumption of normal erythropoietic rates can be explained either on the basis of a sufficient number of cells being produced by overactivity of bone marrow of normal mass, or by an increase in the total mass of hypoactive marrow sufficient to compensate.
In chart 6A the observed erythrocyte level of 2.09 millions per mm.' coincided with that expected from a normal rate of cell production and a rate of random destruction similar to that by which the transfused cells were lost. Treatment with B. was begun 4 days after transfusion and the rate of cell release accelerated to a maximum of nearly twice the normal. A cell count of 5.5 millions was attained about 60 days after the beginning of therapy. With the same assumptions as previously, the expected erythrocyte level in the steady state was computed as 2.31 millions per mm.8, compared to the observed level of 1.7 millions. This discrepancy is barely significant, but inclusion of this case makes the interpretation conservative. Again, the difference between the expected and the normal levels represents the effect of a destructive mechanism. The rise in the erythrocyte counts of the patient exceeded somewhat that expected and probably represents some increase in the rate of cell release to the circulation. Erythrocyte levels attributable' entirely to hemolysis. The four patients from whom data are presented in Figure 6 exhibited observed cell counts during the steady state of random erythrocyte destruction which coincided almost exactly with those expected when computed from the rates of random destruction of the transfused erythrocytes. In three of these cases, also, it is assumed that the rate of random loss of transfused cells during therapy indicated the condition prior to treatment. But in Case 8 ( Figure 6D ) the curve of random cell loss was actually determined for 60 days before treatment and the same correspondence between observed and expected cell levels was obtained. In none of the four cases was there a discrepancy which was attributable to maturation arrest.
It is of interest that in Cases 6 ( Figure 6A ), 5 ( Figure 6B ), and 8 ( Figure 6D ) the rate of erythrocyte release to the circulation apparently accelerated after the inception of therapy and attained approximately twice the normal. In the six cases studied Case 4 ( Figure 6C ) was the single instance where the rise in the erythrocyte counts was exactly that expected on the assumption of a normal rate of erythrocyte release to the circulation and cessation of the random destructive mechanism. It may be of significance that this was the only case in the series in which the initial erythrocyte counts were as high as 3.5 millions per mm."
Analysis of the other clinical and laboratory data (Table I) yields no clue by which to differentiate between patients in whom there was evidence of maturation arrest and those in whom there was not. The height of the reticulocyte counts after therapy with B12 seemed to fall within the expected range. The serum bilirubin levels showed no correlation. The presence or absence of severe disease of the spinal cord was not indicative; nor was age, sex, or duration of the disease. The initial erythrocyte level was not prognostic of the difference.
Validity of interpretations
The methods of indirect mathematical analysis which we have employed are, of course, susceptible to more than one interpretation. For example, we have concluded that maturation arrest in the bone marrow did not affect the erythrocyte level of the untreated patient when the observed cell levels in the steady state of random destruction coincided with the level expected on the assumption of a normal rate of erythrocyte release to the circulation. It is possible that there was decreased erythrocyte release to the circulation and the rate of destruction of the patient's own cells was less than that of normal adult transfused erythrocytes whose rate was actually measured. But this seems improbable on three counts: (a) In Case 10 the erythrocytes from a patient with pernicious anemia were lost at the same rate in a normal subject as were normal adult cells transfused to the patient, (b) it is hardly to be expected that erythrocytes formed in a normal donor would be more sus-
The patient in chart 6B showed an observed cell level of 2.00 millions per mm.' before treatment, which coincided with the expected level. Treatment was begun 4 days after transfusion and the cell release rate attained a maximum of 1.8 times the normal.
In chart 6C the patient's observed erythrocyte level was the same as the expected one. However, after treatment with B,,, the erythrocyte counts increased at the same rate as expected for normal rate of cell release. It is noteworthy that this is the only patient in the series whose initial red cell count, without treatment, was as high as 3.5 millions per mm.'.
The patient in chart 6D was untreated for 65 days of the study and the observed cell levels were as expected. During the short time after treatment was begun the rate of cell release attained double the normal. 
